Myeloid neoplasms after breast cancer: "Therapy-related" not an independent poor prognostic factor

Yiming Chen, Zeev Estrov, Sherry Pierce, Wei Qiao, Gautam Borthakur, Farhad Ravandi, Tapan Kadia, Mark Brandt, Susan O'brien, Elias Jabbour, Guillermo Garcia-Manero, Jorge Cortes, Miloslav Beran

Research output: Contribution to journalArticle

Abstract

Abstract Two hundred and thirty-five consecutive patients presenting to a single center with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after breast cancer treatment were compared with matched patients with de novo AML or MDS. There was no significant difference in median overall survival (OS) times between patients with therapy-related AML and those with de novo AML (8.7 months vs.10.2 months; p = 0.17). Patients with therapy-related MDS had slightly lower median baseline platelet counts and a higher frequency of poor cytogenetics than those with de novo MDS, but the two groups had similar OS times (13.6 months vs. 18.9 months; p = 0.06). Multivariate analysis revealed that cytogenetic risk, baseline white blood cell count, age and performance status were predictive for OS time in AML and that cytogenetic risk and performance status were predictive for OS time in MDS. Having therapy-related disease is not an independent risk factor in patients with myeloid neoplasms and with a history of breast cancer. Clinical trials should be designed to serve both populations.

Original languageEnglish (US)
Pages (from-to)1012-1019
Number of pages8
JournalLeukemia and Lymphoma
Volume56
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Myelodysplastic Syndromes
Acute Myeloid Leukemia
Breast Neoplasms
Cytogenetics
Survival
Neoplasms
Therapeutics
Platelet Count
Leukocyte Count
Multivariate Analysis
Clinical Trials
Population

Keywords

  • Chemotherapeutic approaches
  • Myeloid leukemias and dysplasias
  • Prognostication

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Chen, Y., Estrov, Z., Pierce, S., Qiao, W., Borthakur, G., Ravandi, F., ... Beran, M. (2015). Myeloid neoplasms after breast cancer: "Therapy-related" not an independent poor prognostic factor. Leukemia and Lymphoma, 56(4), 1012-1019. https://doi.org/10.3109/10428194.2014.946023

Myeloid neoplasms after breast cancer : "Therapy-related" not an independent poor prognostic factor. / Chen, Yiming; Estrov, Zeev; Pierce, Sherry; Qiao, Wei; Borthakur, Gautam; Ravandi, Farhad; Kadia, Tapan; Brandt, Mark; O'brien, Susan; Jabbour, Elias; Garcia-Manero, Guillermo; Cortes, Jorge; Beran, Miloslav.

In: Leukemia and Lymphoma, Vol. 56, No. 4, 01.04.2015, p. 1012-1019.

Research output: Contribution to journalArticle

Chen, Y, Estrov, Z, Pierce, S, Qiao, W, Borthakur, G, Ravandi, F, Kadia, T, Brandt, M, O'brien, S, Jabbour, E, Garcia-Manero, G, Cortes, J & Beran, M 2015, 'Myeloid neoplasms after breast cancer: "Therapy-related" not an independent poor prognostic factor', Leukemia and Lymphoma, vol. 56, no. 4, pp. 1012-1019. https://doi.org/10.3109/10428194.2014.946023
Chen, Yiming ; Estrov, Zeev ; Pierce, Sherry ; Qiao, Wei ; Borthakur, Gautam ; Ravandi, Farhad ; Kadia, Tapan ; Brandt, Mark ; O'brien, Susan ; Jabbour, Elias ; Garcia-Manero, Guillermo ; Cortes, Jorge ; Beran, Miloslav. / Myeloid neoplasms after breast cancer : "Therapy-related" not an independent poor prognostic factor. In: Leukemia and Lymphoma. 2015 ; Vol. 56, No. 4. pp. 1012-1019.
@article{e33502867ea0479bb896fb9425c8a766,
title = "Myeloid neoplasms after breast cancer: {"}Therapy-related{"} not an independent poor prognostic factor",
abstract = "Abstract Two hundred and thirty-five consecutive patients presenting to a single center with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after breast cancer treatment were compared with matched patients with de novo AML or MDS. There was no significant difference in median overall survival (OS) times between patients with therapy-related AML and those with de novo AML (8.7 months vs.10.2 months; p = 0.17). Patients with therapy-related MDS had slightly lower median baseline platelet counts and a higher frequency of poor cytogenetics than those with de novo MDS, but the two groups had similar OS times (13.6 months vs. 18.9 months; p = 0.06). Multivariate analysis revealed that cytogenetic risk, baseline white blood cell count, age and performance status were predictive for OS time in AML and that cytogenetic risk and performance status were predictive for OS time in MDS. Having therapy-related disease is not an independent risk factor in patients with myeloid neoplasms and with a history of breast cancer. Clinical trials should be designed to serve both populations.",
keywords = "Chemotherapeutic approaches, Myeloid leukemias and dysplasias, Prognostication",
author = "Yiming Chen and Zeev Estrov and Sherry Pierce and Wei Qiao and Gautam Borthakur and Farhad Ravandi and Tapan Kadia and Mark Brandt and Susan O'brien and Elias Jabbour and Guillermo Garcia-Manero and Jorge Cortes and Miloslav Beran",
year = "2015",
month = "4",
day = "1",
doi = "10.3109/10428194.2014.946023",
language = "English (US)",
volume = "56",
pages = "1012--1019",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Myeloid neoplasms after breast cancer

T2 - "Therapy-related" not an independent poor prognostic factor

AU - Chen, Yiming

AU - Estrov, Zeev

AU - Pierce, Sherry

AU - Qiao, Wei

AU - Borthakur, Gautam

AU - Ravandi, Farhad

AU - Kadia, Tapan

AU - Brandt, Mark

AU - O'brien, Susan

AU - Jabbour, Elias

AU - Garcia-Manero, Guillermo

AU - Cortes, Jorge

AU - Beran, Miloslav

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Abstract Two hundred and thirty-five consecutive patients presenting to a single center with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after breast cancer treatment were compared with matched patients with de novo AML or MDS. There was no significant difference in median overall survival (OS) times between patients with therapy-related AML and those with de novo AML (8.7 months vs.10.2 months; p = 0.17). Patients with therapy-related MDS had slightly lower median baseline platelet counts and a higher frequency of poor cytogenetics than those with de novo MDS, but the two groups had similar OS times (13.6 months vs. 18.9 months; p = 0.06). Multivariate analysis revealed that cytogenetic risk, baseline white blood cell count, age and performance status were predictive for OS time in AML and that cytogenetic risk and performance status were predictive for OS time in MDS. Having therapy-related disease is not an independent risk factor in patients with myeloid neoplasms and with a history of breast cancer. Clinical trials should be designed to serve both populations.

AB - Abstract Two hundred and thirty-five consecutive patients presenting to a single center with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after breast cancer treatment were compared with matched patients with de novo AML or MDS. There was no significant difference in median overall survival (OS) times between patients with therapy-related AML and those with de novo AML (8.7 months vs.10.2 months; p = 0.17). Patients with therapy-related MDS had slightly lower median baseline platelet counts and a higher frequency of poor cytogenetics than those with de novo MDS, but the two groups had similar OS times (13.6 months vs. 18.9 months; p = 0.06). Multivariate analysis revealed that cytogenetic risk, baseline white blood cell count, age and performance status were predictive for OS time in AML and that cytogenetic risk and performance status were predictive for OS time in MDS. Having therapy-related disease is not an independent risk factor in patients with myeloid neoplasms and with a history of breast cancer. Clinical trials should be designed to serve both populations.

KW - Chemotherapeutic approaches

KW - Myeloid leukemias and dysplasias

KW - Prognostication

UR - http://www.scopus.com/inward/record.url?scp=84929069799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929069799&partnerID=8YFLogxK

U2 - 10.3109/10428194.2014.946023

DO - 10.3109/10428194.2014.946023

M3 - Article

C2 - 25048874

AN - SCOPUS:84929069799

VL - 56

SP - 1012

EP - 1019

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -